Skip to main content

Advertisement

Log in

Unmet Challenges in Immune-Mediated Hepatobiliary Diseases

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

It is ironic that the liver, which serves a critical function in immune tolerance, itself becomes the victim of an autoimmune attack. Indeed, liver autoimmunity and the autoimmune diseases associated with both innate and adaptive responses to hepatocytes and/or cholangiocytes are models of human autoimmunity. For example, in primary biliary cirrhosis, there exists a well-defined and characteristic autoantibody and considerable homogeneity between patients. In autoimmune hepatitis, there are clinical characteristics that allow a rigorous subset definition and well-defined inflammatory infiltrates. In both cases, there are defects in a variety of immune pathways and including regulatory cells. In primary sclerosing cholangitis, with its characteristic overlap with inflammatory bowel disease, there are unique defects in innate immunity and particular important contribution of lymphoid homing to disease pathogenesis. In these diseases, as with other human autoimmune processes, there is the critical understanding that pathogenesis requires a genetic background, but is determined by environmental features, and indeed the concordance of these diseases in identical twins highlights the stochastic nature of immunopathology. Unfortunately, despite major advances in basic immunology and in immunopathology in these diseases, there remains a major void in therapy. The newer biologics that are so widely used in rheumatology, neurology, and gastroenterology have not yet seen success in autoimmune liver disease. Future efforts will depend on more rigorous molecular biology and systems analysis in order for successful application to be made to patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mackay IR, Burnet F (1963) Autoimmune Diseases. Charles C. Thomas, Springfield

    Google Scholar 

  2. Berrih-Aknin S (2014) Myasthenia Gravis: paradox versus paradigm in autoimmunity. J Autoimmun 52:1–28

    Article  CAS  PubMed  Google Scholar 

  3. Collin R, Dugas V, Chabot-Roy G, et al (2015) Autoimmunity and antibody affinity maturation are modulated by genetic variants on mouse chromosome 12. J Autoimmun

  4. Cui Y, Sheng Y, Zhang X (2013) Genetic susceptibility to SLE: recent progress from GWAS. J Autoimmun 41:25–33

    Article  CAS  PubMed  Google Scholar 

  5. de Boer YS, van Gerven NM, Zwiers A et al (2014) Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 147:443–452, e445

    Article  PubMed  Google Scholar 

  6. Gatselis NK, Zachou K, Koukoulis GK, Dalekos GN (2015) Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics. World J Gastroenterol 21:60–83

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Hirschfield GM, Karlsen TH (2014) Genetic risks link autoimmune hepatitis to other autoimmune liver disease. Gastroenterology 147:270–273

    Article  PubMed  Google Scholar 

  8. Juran BD, Lazaridis KN (2014) Environmental factors in primary biliary cirrhosis. Semin Liver Dis 34:265–272

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Kopec AK, Sullivan BP, Kassel KM, Joshi N, Luyendyk JP (2014) Toxicogenomic analysis reveals profibrogenic effects of trichloroethylene in autoimmune-mediated cholangitis in mice. Toxicol Sci 141:515–523

    Article  CAS  PubMed  Google Scholar 

  10. Lu Q (2013) The critical importance of epigenetics in autoimmunity. J Autoimmun 41:1–5

    Article  PubMed  Google Scholar 

  11. Lugli EB, Correia R, Fischer R et al (2015) Expression of citrulline and homocitrulline residues in the lungs of non-smokers and smokers: implications for autoimmunity in rheumatoid arthritis. Arthritis Res Ther 17:9

    Article  PubMed Central  PubMed  Google Scholar 

  12. Wang L, Wang FS, Chang C, Gershwin ME (2014) Breach of tolerance: primary biliary cirrhosis. Semin Liver Dis 34:297–317

    Article  PubMed  Google Scholar 

  13. Yang W, Yao Y, Yang YQ et al (2014) Differential modulation by IL-17A of Cholangitis versus Colitis in IL-2Ralpha deleted mice. PLoS One 9:e105351

    Article  PubMed Central  PubMed  Google Scholar 

  14. Zhang P, Zhao M, Liang G et al (2013) Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris. J Autoimmun 41:17–24

    Article  PubMed  Google Scholar 

  15. Hirschfield GM, Gershwin ME (2013) The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 8:303–330

    Article  CAS  PubMed  Google Scholar 

  16. Agmon-Levin N, Arango MT, Kivity S et al (2014) Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model. J Autoimmun 54:21–32

    Article  CAS  PubMed  Google Scholar 

  17. Castiella A, Zapata E, Lucena MI, Andrade RJ (2014) Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease. World J Hepatol 6:160–168

    Article  PubMed Central  PubMed  Google Scholar 

  18. Chen RC, Naiyanetr P, Shu SA et al (2013) Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. Hepatology 57:1498–1508

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Coit P, Yalavarthi S, Ognenovski M, et al (2015) Epigenome profiling reveals significant DNA demethylation of interferon signature genes in lupus neutrophils. J Autoimmun

  20. deLemos AS, Foureau DM, Jacobs C, Ahrens W, Russo MW, Bonkovsky HL (2014) Drug-induced liver injury with autoimmune features. Semin Liver Dis 34:194–204

    Article  CAS  PubMed  Google Scholar 

  21. Fan Y, Gualtierotti G, Tajima A et al (2014) Compromised central tolerance of ICA69 induces multiple organ autoimmunity. J Autoimmun 53:10–25

    Article  CAS  PubMed  Google Scholar 

  22. Katoh H, Zheng P, Liu Y (2013) FOXP3: genetic and epigenetic implications for autoimmunity. J Autoimmun 41:72–78

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Leung PS, Wang J, Naiyanetr P et al (2013) Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA. J Autoimmun 41:79–86

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Wang Q, Selmi C, Zhou X et al (2013) Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun 41:140–145

    Article  PubMed  Google Scholar 

  25. Zhao M, Liu S, Luo S et al (2014) DNA methylation and mRNA and microRNA expression of SLE CD4+ T cells correlate with disease phenotype. J Autoimmun 54:127–136

    Article  CAS  PubMed  Google Scholar 

  26. Adutler-Lieber S, Zaretsky I, Platzman I et al (2014) Engineering of synthetic cellular microenvironments: implications for immunity. J Autoimmun 54:100–111

    Article  CAS  PubMed  Google Scholar 

  27. Ando Y, Yang GX, Kenny TP et al (2013) Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-beta receptor type II mouse. J Autoimmun 41:111–119

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Bowlus CL, Gershwin ME (2014) The diagnosis of primary biliary cirrhosis. Autoimmun Rev 13:441–444

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Chang CH, Chen YC, Yu YH et al (2014) Innate immunity drives xenobiotic-induced murine autoimmune cholangitis. Clin Exp Immunol 177:373–380

    Article  CAS  PubMed  Google Scholar 

  30. Fuchs S, Aricha R, Reuveni D, Souroujon MC (2014) Experimental autoimmune myasthenia gravis (EAMG): from immunochemical characterization to therapeutic approaches. J Autoimmun 54:51–59

    Article  CAS  PubMed  Google Scholar 

  31. Gershwin ME, Krawitt EL (2014) Autoimmune hepatitis: 50 years of (slow) progress. Hepatology 59:754–756

    Article  PubMed Central  PubMed  Google Scholar 

  32. Huang W, Kachapati K, Adams D et al (2014) Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells. J Autoimmun 50:123–134

    Article  CAS  PubMed  Google Scholar 

  33. Hudspeth K, Pontarini E, Tentorio P et al (2013) The role of natural killer cells in autoimmune liver disease: a comprehensive review. J Autoimmun 46:55–65

    Article  CAS  PubMed  Google Scholar 

  34. Kar SP, Seldin MF, Chen W et al (2013) Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. Genes Immun 14:179–186

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Kawata K, Tsuda M, Yang GX et al (2013) Identification of potential cytokine pathways for therapeutic intervention in murine primary biliary cirrhosis. PLoS One 8:e74225

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Kawata K, Yang GX, Ando Y et al (2013) Clonality, activated antigen-specific CD8(+) T cells, and development of autoimmune cholangitis in dnTGFbetaRII mice. Hepatology 58:1094–1104

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Kurth MJ, Yokoi T, Gershwin ME (2014) Halothane-induced hepatitis: paradigm or paradox for drug-induced liver injury. Hepatology 60:1473–1475

    Article  CAS  PubMed  Google Scholar 

  38. Lleo A, Oertelt-Prigione S, Bianchi I et al (2013) Y chromosome loss in male patients with primary biliary cirrhosis. J Autoimmun 41:87–91

    Article  PubMed  Google Scholar 

  39. Lleo A, Zhang W, McDonald WH et al (2014) Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. Hepatology 60:1314–1323

    Article  CAS  PubMed  Google Scholar 

  40. Mayer CT, Ghorbani P, Kuhl AA et al (2014) Few Foxp3(+) regulatory T cells are sufficient to protect adult mice from lethal autoimmunity. Eur J Immunol 44:2990–3002

    Article  CAS  PubMed  Google Scholar 

  41. Ridgway WM, Gershwin ME (2014) Prometheus unbound: NKT cells inhibit hepatic regeneration. Hepatology 60:1133–1135

    Article  PubMed  Google Scholar 

  42. Selmi C, Cavaciocchi F, Lleo A et al (2014) Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis. Front Immunol 5:128

    PubMed Central  PubMed  Google Scholar 

  43. Sthoeger Z, Sharabi A, Mozes E (2014) Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus. J Autoimmun 54:60–71

    Article  CAS  PubMed  Google Scholar 

  44. Tanaka H, Yang GX, Iwakoshi N et al (2013) Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. Clin Exp Immunol 174:364–371

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Tanaka H, Zhang W, Yang GX et al (2014) Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3(+) regulatory T cells. Clin Exp Immunol 178:253–261

    Article  CAS  PubMed  Google Scholar 

  46. Wang J, Budamagunta MS, Voss JC et al (2013) Antimitochondrial antibody recognition and structural integrity of the inner lipoyl domain of the E2 subunit of pyruvate dehydrogenase complex. J Immunol 191:2126–2133

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Wang J, Yang GX, Tsuneyama K, Gershwin ME, Ridgway WM, Leung PS (2014) Animal models of primary biliary cirrhosis. Semin Liver Dis 34:285–296

    Article  CAS  PubMed  Google Scholar 

  48. Wang L, Sun Y, Zhang Z et al (2015) CXCR5(+) CD4(+) T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis. Hepatology 61:627–638

    Article  CAS  PubMed  Google Scholar 

  49. Xu X, Zhang S, Jin R et al (2015) Retention and tolerance of autoreactive CD4(+) recent thymic emigrants in the liver. J Autoimmun 56:87–97

    Article  CAS  PubMed  Google Scholar 

  50. Yang CY, Ma X, Tsuneyama K et al (2014) IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatology 59:1944–1953

    Article  CAS  PubMed  Google Scholar 

  51. Yao Y, Yang W, Yang YQ et al (2014) Distinct from its canonical effects, deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2Ralpha(−/−) mice. J Autoimmun 51:99–108

    Article  CAS  PubMed  Google Scholar 

  52. Zhang J, Zhang W, Leung PS et al (2014) Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology 60:1708–1716

    Article  CAS  PubMed  Google Scholar 

  53. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ (2009) Primary biliary cirrhosis. Hepatology 50:291–308

    Article  PubMed  Google Scholar 

  54. European Association for the Study of the Liver (2009) EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 51:237–267

    Article  Google Scholar 

  55. Boonstra K, Beuers U, Ponsioen CY (2012) Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 56:1181–1188

    Article  PubMed  Google Scholar 

  56. Hirschfield G M, Siminovitch K A, (2014) Genetics in PBC: what do the “risk genes” teach us? Clin Rev Allergy Immunol

  57. Dong M, Li J, Tang R, et al (2015) Multiple genetic variants associated with primary biliary Cirrhosis in a Han Chinese Population. Clin Rev Allergy Immunol

  58. Gershwin ME, Mackay IR (2008) The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 47:737–745

    Article  PubMed  Google Scholar 

  59. Beuers U, Hohenester S, de Buy Wenniger LJ, Kremer AE, Jansen PL, Elferink RP (2010) The biliary HCO(3)(−) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 52:1489–1496

    Article  CAS  PubMed  Google Scholar 

  60. Medina JF, Martinez A, Vazquez JJ, Prieto J (1997) Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 25:12–17

    Article  CAS  PubMed  Google Scholar 

  61. Liaskou E, Hirschfield GM, Gershwin ME (2014) Mechanisms of tissue injury in autoimmune liver diseases. Semin Immunopathol 36:553–568

    Article  CAS  PubMed  Google Scholar 

  62. Pollheimer M J, Fickert P, (2014) Animal models in primary biliary cirrhosis and primary sclerosing cholangitis. Clin Rev Allergy Immunol

  63. Floreani A, Spinazze A, Caballeria L, et al (2014) Extrahepatic malignancies in primary biliary cirrhosis: a comparative study at two European centers. Clin Rev Allergy Immunol

  64. Sun Y, Zhang W, Li B, Zou Z, Selmi C, Gershwin M E, (2015) The coexistence of sjogren’s syndrome and primary biliary cirrhosis: a comprehensive review. Clin Rev Allergy Immunol

  65. Sun Y, Haapanen K, Li B, Zhang W, Van de Water J, Gershwin, M E (2014) Women and primary biliary cirrhosis. Clin Rev Allergy Immunol

  66. Floreani A, Infantolino C, Franceschet I, et al (2014) Pregnancy and primary biliary cirrhosis: a case–control study. Clin Rev Allergy Immunol

  67. Corpechot C, Abenavoli L, Rabahi N et al (2008) Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48:871–877

    Article  CAS  PubMed  Google Scholar 

  68. Corpechot C, Chazouilleres O, Poupon R (2011) Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 55:1361–1367

    Article  CAS  PubMed  Google Scholar 

  69. Lammers WJ, van Buuren HR, Hirschfield GM et al (2014) Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 147:1338–1349.e5, quiz e1315

    Article  CAS  PubMed  Google Scholar 

  70. Pares A, Caballeria L, Rodes J (2006) Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 130:715–720

    Article  CAS  PubMed  Google Scholar 

  71. Floreani A, Franceschet I, Perini L, Cazzagon N, Gershwin M E, Bowlus C L, (2014) New therapies for primary biliary cirrhosis. Clin Rev Allergy Immunol

  72. Dyson J K, Hirschfield G M, Adams D H, et al (2015) Novel therapeutic targets in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol

  73. Beuers U, Trauner M, Jansen P, Poupon R (2015) New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatology 62, in press

  74. Griffiths L, Jones DE (2014) Pathogenesis of primary biliary cirrhosis and its fatigue. Dig Dis 32:615–625

    Article  PubMed  Google Scholar 

  75. Beuers U, Kremer AE, Bolier R, Elferink RP (2014) Pruritus in cholestasis: facts and fiction. Hepatology 60:399–407

    Article  CAS  PubMed  Google Scholar 

  76. Folseraas T, Liaskou E, Anderson C A, Karlsen T H (2014) Genetics in PSC: What do the “risk genes” teach us? Clin Rev Allergy Immunol

  77. Karlsen TH, Franke A, Melum E et al (2010) Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 138:1102–1111

    Article  PubMed  Google Scholar 

  78. Folseraas T, Melum E, Rausch P et al (2012) Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol 57:366–375

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  79. Maroni L, van de Graaf S F, Hohenester S D, Oude Elferink R P, Beuers U (2014) Fucosyltransferase 2: a genetic risk factor for primary sclerosing cholangitis and crohn’s disease-a comprehensive review. Clin Rev Allergy Immunol

  80. Keitel V, Reich M, Haussinger D (2014) TGR5: pathogenetic role and/or therapeutic target in fibrosing cholangitis? Clin Rev Allergy Immunol

  81. Hohenester S, Wenniger LM, Paulusma CC et al (2012) A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 55:173–183

    Article  CAS  PubMed  Google Scholar 

  82. Fickert P, Pollheimer MJ, Beuers U et al (2014) Characterization of animal models for primary sclerosing cholangitis (PSC). J Hepatol 60:1290–1303

    Article  PubMed  Google Scholar 

  83. Liaskou E, Jeffery LE, Trivedi PJ et al (2014) Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis. Gastroenterology 147(221–232):e227

    Google Scholar 

  84. Chapman R, Fevery J, Kalloo A et al (2010) Diagnosis and management of primary sclerosing cholangitis. Hepatology 51:660–678

    Article  CAS  PubMed  Google Scholar 

  85. Hubers L M, Maillette de Buy Wenniger L J, Doorenspleet M E, et al (2014) IgG4-associated cholangitis: a comprehensive review. Clin Rev Allergy Immunol

  86. de Buy M, Wenniger LJ, Doorenspleet ME, Klarenbeek PL et al (2013) Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. Hepatology 57:2390–2398

    Article  Google Scholar 

  87. Wallace ZS, Mattoo H, Carruthers M et al (2015) Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis 74:190–195

    Article  CAS  PubMed  Google Scholar 

  88. de Buy Wenniger LJ, Culver EL, Beuers U (2014) Exposure to occupational antigens might predispose to IgG4-related disease. Hepatology 60:1453–1454

    Article  PubMed  Google Scholar 

  89. Ghazale A, Chari ST, Zhang L et al (2008) Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 134:706–715

    Article  PubMed  Google Scholar 

  90. Gong YZ, Nititham J, Taylor K et al (2014) Differentiation of follicular helper T cells by salivary gland epithelial cells in primary Sjogren’s syndrome. J Autoimmun 51:57–66

    Article  CAS  PubMed  Google Scholar 

  91. Invernizzi P, Gershwin ME (2014) New therapeutics in primary biliary cirrhosis: will there ever be light? Liver Int 34:167–170

    Article  PubMed  Google Scholar 

  92. Seror R, Theander E, Bootsma H et al (2014) Outcome measures for primary Sjogren’s syndrome: a comprehensive review. J Autoimmun 51:51–56

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ulrich Beuers.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beuers, U., Gershwin, M.E. Unmet Challenges in Immune-Mediated Hepatobiliary Diseases. Clinic Rev Allerg Immunol 48, 127–131 (2015). https://doi.org/10.1007/s12016-015-8484-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-015-8484-9

Keywords

Navigation